Fig. 7: Total HA-specific antibody response quantified by ELISA. | npj Vaccines

Fig. 7: Total HA-specific antibody response quantified by ELISA.

From: Recombinant HA-based vaccine outperforms split and subunit vaccines in elicitation of influenza-specific CD4 T cells and CD4 T cell-dependent antibody responses in humans

Fig. 7

Total HA-specific antibody responses of subjects vaccinated with Fluzone (blue), Flucelvax (gold) or Flublok (red) are shown. Anti-HA antibody levels collected before vaccination and day 14 post vaccination were measured by HA-specific IgG ELISA assays. The relative titers were quantified based on the dilution of antibodies required to reach a fixed OD405 signal on the linear portion of the antibody titration curve. Shown in panel a is the fold-change between day 0 and day 14 (D14/D0) for each of the HA strains contained in the vaccine, H1 (top left), H3 (top right), HA-B Brisbane (Victoria lineage, bottom left) and HA-B Florida (a surrogate for B/Phuket, Yamagata lineage, bottom right). Responses among individuals are represented by the scatter and the geometric mean is indicated by a black line. A dotted line indicates the fourfold response. The p values shown were calculated by the Wilcoxon rank sum test. In b, the table below, indicates the percent responders for each vaccine. The vaccine is indicated to the left and the specific HA protein on the columns above, based on a fourfold or greater response.

Back to article page